BioSpace News Archive

Drug Development

Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder

Vistagen today announced positive data from its Phase 3 open-label study designed to evaluate the safety and tolerability of multiple, as-needed intranasal administrations of fasedienol (PH94B) over time in adults with social anxiety disorder (SAD).

March 22, 2023
·
10 min read
Bio NC

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. announced today that the Company has been issued a patent by the United States Patent and Trademark Office (USPTO) with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension associated with HFpEF.

March 22, 2023
·
6 min read
BioMidwest

AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application

AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

March 22, 2023
·
4 min read
Andira Advances Lead Cannabinoid Compositions for Metastatic Breast Cancer through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia

Andira Pharmaceuticals announces it will carry out pharmacologic characterization of its lead compounds for metastatic breast cancer through a collaborative research program with the University of British Columbia (UBC), Vancouver.

March 22, 2023
·
3 min read
EVOKE Presentation Awarded Overall Winner at ASIPP Annual Meeting

Saluda Medical Pty Limited announced that the EVOKE 36-month Study received the Outstanding Achievement in Research Award at the 25th annual meeting of the American Society of Interventional Pain Physicians in National Harbor, MD.

March 22, 2023
·
3 min read
Sequana Medical announces additional patents for DSR® in China and the United States

Sequana Medical NV announces further strengthening of the intellectual property portfolio for its DSR program.

March 22, 2023
·
6 min read
IRLAB: Invitation to symposium on Parkinson’s Disease and its Management Dilemma at the AD/PD(TM) 2023 on March 31, 2023

IRLAB Therapeutics AB announced an invitation to its industry symposium at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders on Friday, March 31, 2023.

March 22, 2023
·
2 min read
XNK presents at the 8th Innate Killer Summit in La Jolla, San Diego

XNK Therapeutics AB announced its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.

March 22, 2023
·
2 min read
Genetown

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Pyxis Oncology, Inc., a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported financial results for the full year ended December 31, 2022, and provided a corporate update.

March 22, 2023
·
8 min read
Drug Development

Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden

Alzheon, Inc. announced that it will be presenting interim findings from an ongoing Phase 2 study evaluating ALZ-801 tablet at the upcoming AD/PD 2023 Conference to be held from March 28 – April 1, 2023 in Gothenburg, Sweden.

March 22, 2023
·
9 min read